Navigation Links
Rigel Announces Fourth Quarter and Year End 2007 Financial Results
Date:2/12/2008

elopment programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to the timing of results of Rigel's clinical development of product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "indicates," "promising," "expects," "anticipates" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates, as well as other risks detailed from time to time in Rigel's reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended September 30, 2007. Rigel does not undertake any obligation to update forward-looking statements.

Contact: Ryan D. Maynard

Phone: 650.624.1284

Email: invrel@rigel.com

Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.

Phone: 650.430.3777

Email: susan@alchemyemail.com

STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

(unaudited) (unaudited)

Revenues:

Contract revenues from

collaborations $8,000
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Rigel to Present at BIO Investor Forum 2007
2. Rigel to Present Research Programs at Scientific Conferences
3. Rigel Announces Pricing of Public Offering of Common Stock
4. Rigel to Present at BIO CEO & Investor Conference
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 EPFL and the University of  ... of John P. Donoghue . The American neuroscientist ... . The new Wyss Center for ... Geneva , has named as its director ... P. Donoghue , founder of Brown University,s Institute for ...
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded for ... a second treatment cup to help prevent and smooth skin ... thinner on the edges for a softer contact with the ... surfaces on the face, neck and décolleté. Choose to use ... such as the cheeks and neck, or opt for the ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., Inc. ... developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), ... nutritional products in the People,s Republic of China, today ... December 31, 2010. Fiscal 2010 Financial ...
... Although top bio-pharmaceutical companies agree that Key Opinion ... a new product, increasing competition has made it difficult ... role of Medical Science Liaisons (MSLs) in forging relationships ... years. In fact, today, MSL ...
... 2011 Reportlinker.com announces that a new market ... Global Angiongenesis Inhibitors and ... This report analyzes the ... in US$ Million by the following product ...
Cached Biology Technology:Weikang Bio-Technology Announces Fiscal 2010 Financial Results 2Weikang Bio-Technology Announces Fiscal 2010 Financial Results 3Weikang Bio-Technology Announces Fiscal 2010 Financial Results 4Weikang Bio-Technology Announces Fiscal 2010 Financial Results 5Weikang Bio-Technology Announces Fiscal 2010 Financial Results 6Weikang Bio-Technology Announces Fiscal 2010 Financial Results 7Newly Updated for 2011: Medical Science Liaison Study Shows Growth in KOL Outreach, Impact 2Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 2Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 3Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 4Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 5Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 6Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 7Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 8Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 9Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 10Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 11Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 12Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 13Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 14Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 15Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 16Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 17
(Date:7/10/2014)... and other major cities in New Mexico, nearly every ... wastewater rather than precious potable water supplies. Across the ... all golf courses receive treated effluent. Reusing the effluent ... golf courses and homeowners alike fertilize their lawns during ... nitrate. A New Mexico State University turfgrass expert has ...
(Date:7/10/2014)... Mass. , June 30, 2014  Aware, Inc. ... biometrics software and services, previously announced on June 26, ... special cash dividend of $1.75 per share, or approximately ... date of July 10, 2014 and a payment date ... by NASDAQ that it had set an ex-dividend date ...
(Date:7/10/2014)... 2014 It is a great honor for ... of the world-renowned Thoracic and Cardiovascular surgeon, Mark E ... Dr. Ginsburg, with over 34 years of experience, is ... Good Samaritan Regional Medical Center. Dr. Ginsburg has been ... and is considered an expert in the implantation of ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... , BOSTON -- October 17, 2011-- In a paper published ... headed by Mary R. Loeken, PhD, has identified the enzyme AMP ... the risk of neural tube defects such as spina bifida and ... Even if women with diabetes -- either type 1 or ...
... polyester which occurs naturally in bacteria as Ralstonia ... PHB is biodegradable and is not dependent on fossil ... produce to replace petroleum-based plastics. New research reported in ... describes an alternative method of producing PHB in ...
... have found a way to inject a precise dose of ... without a needle. The technique uses electricity to "shoot" ... a cell in a fraction of a second. L. ... the technique in the online edition of the journal ...
Cached Biology News:Joslin study finds clue to birth defects in babies of mothers with diabetes 2Researchers do precise gene therapy without a needle 2Researchers do precise gene therapy without a needle 3
Tracker Datamatrix RS-1* reads 96 2D Bar-coded tubes within 20 seconds....
Request Info...
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C ... Cl N O 6 ,M.W.= ... ,Solution: Clear (2% in DMF) ,Biological ... and M13 ,Elemental Analysis: Agrees with ...
...
Biology Products: